fullerene c60 has been researched along with Coronary Thrombosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, X; Chang, Y; Chen, K; Gu, W; Li, J; Liu, J; Xia, S; Xing, G; Zeng, L; Zhao, L; Zu, M | 1 |
1 other study(ies) available for fullerene c60 and Coronary Thrombosis
| Article | Year |
|---|---|
Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa.
Topics: Animals; Anticoagulants; Blood Coagulation; Coronary Thrombosis; Factor Xa; Fullerenes; Nanoparticles; Rats; Rats, Sprague-Dawley; Thrombin | 2018 |